BRAF and non-small cell lung carcinoma: As of May 2019, the FDA has approved a total of three BRAF/MEK combination regimens, with the dabrafenib and trametinib combination being indicated for the treatment of BRAF-V600-positive melanoma, non-small cell lung cancer and anaplastic thyroid cancer (Table 4).